Join to access to all OVN content. Join for Free

Results for 'Transporter Inhibition Data'

...
OVN Avatar Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 8th • 5 mins read

...
Partner Avatar Tom Caravela
MSL Hiring and Recruitment: 5 Ways to Support Diversity and Inclusion

May 18th • 2 mins read

...
Partner Avatar Bridget Rasmusson
Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

Oct 11th • 1 min read

...
Partner Avatar Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge

Apr 4th • 1 min read

...
Partner Avatar iNIZIO
Virtual Oncology MSL Team Increases KOL Engagement by 120%

Sep 2nd • 1 min read

...
Partner Avatar iNIZIO
Clinical Educator Oncology Program Improves Adherence by 29%​

Sep 2nd • 1 min read

...
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

May 15th • 5 mins read

...
Partner Avatar iNIZIO
Expert perspectives live from ASCO® 2025

Jul 1st • 1 min read

...
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Apr 19th • 8 mins read

...
OVN Avatar Pai, Rekha
Advances in basic research in oncology in 2020: Bridging basic science and clinical care

Mar 23rd • 1 min read

...
OVN Avatar Adela Rodriguez, Francis Esposito, Helena Oliveres, Ferran Torres and Joan Maurel
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Feb 10th • 3 mins read

...
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Feb 10th • 4 mins read

...
OVN Avatar Ioannis Tsagakis and Maria Papatriantafyllou
Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic

Nov 21st • 3 mins read

...
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Leveraging existing data to contextualize phase II clinical trial findings in oncology

Sep 20th • 3 mins read

...
OVN Avatar Ramez Kouzy , Joseph Abi Jaoude , Walker Mainwaring , Timothy A. Lin , Austin B. Miller , Amit Jethanandani , Andres F. Espinoza , Vivek Verma , Clifton D. Fuller , Bruce D. Minsky , Claus Rödel , Cullen M. Taniguchi , Ethan B. Ludmir
Professional Medical Writer Assistance in Oncology Clinical Trials

Sep 16th • 7 mins read

...
OVN Avatar Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Aug 30th • 16 mins read

...
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Jun 25th • 18 mins read

...
OVN Avatar Melissa H. Roberts & Gary T. Ferguson
Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions

Jun 17th • 6 mins read

...
OVN Avatar Eric Q. Konnick
The regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulation

May 21st • 8 mins read

...
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility

Apr 28th • 8 mins read

Related Topics

Loading...